Newsroom

Sorted by: Latest

-

コモーション・グローバル2025がリヤドで閉幕、画期的な提携とグローバル・モビリティの飛躍を示す

サウジアラビア、リヤド--(BUSINESS WIRE)--(ビジネスワイヤ) -- コモーション・グローバル2025は、世界中の意思決定者、業界リーダー、都市行政の幹部、イノベーター、投資家が一堂に会し、サウジアラビアおよび世界のモビリティの未来を描く変革的な3日間を終えました。今回初めてリヤドのキング・アブドゥッラー金融地区(KAFD)で開催された本イベントでは、次世代交通、サステナビリティのリーダーシップ、都市イノベーションにおけるサウジアラビア王国の加速する役割が示されました。 3日間で100を超えるセッションが開催されたコモーション・グローバルでは、先進的なモビリティ戦略、マルチモーダル交通のブレークスルー、都市のデジタル変革、AIの応用、そして世界の都市における人とモノの移動を劇的に再考する取り組みが紹介されました。 イベントの主なハイライト: MITとKearneyによるレポート 「Envisioning the Future of Mobility Powered by AI(AIを活用したモビリティの未来を描く)」を発表:AIのモビリティ分野における潜在力を最大限に...
-

The 2025 Top 25 Historic Hotels of America® Most Magnificent Gingerbread Displays List Is Announced

WASHINGTON--(BUSINESS WIRE)--The 2025 Top 25 Historic Hotels of America® Most Magnificent Gingerbread Displays List Is Announced...
-

Balyasny Asset Management LP UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest S&P 500 Dividend Aristocrats Target Income UCITS ETF 09.12.2025 KNG.LN IE000SNMGYT5 200,002.00 USD 4,035,158.64 20.176  ...
-

Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive data from the Phase III lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, early-stage breast cancer. At the pre-specified interim analysis, adjuvant giredestrant significantly reduced the risk of invasive di...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - November 09.12.2025 GNOV LN IE000OJ31JQ4 1,250,002.00 USD 43,506,106.87 34.805  ...
-

MED Institute and Sus Clinicals Announce Strategic Collaboration to Advance Preclinical Testing for Medical Product Innovation

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--MED Institute and Sus Clinicals partner to advance preclinical testing, accelerating innovation and improving outcomes for medical products....
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF- August 09.12.2025 GAUG LN IE000TGSG3Y5 650,002.00 USD 22,775,697.27 35.039  ...
-

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). The primary endpoint analysis showed a 35.9% reduction in the risk of disease progression or death amon...
-

Stratasys Supercharges Airbus Production: More Than 25,000 Parts 3D-Printed this Year; 200,000+ Already in Flight

MINNETONKA, Minn. & REHOVOT, Israel--(BUSINESS WIRE)--Powered by Stratasys (NASDAQ: SSYS) technology, Airbus is producing more than 25,000 flight-ready 3D-printed parts annually, transforming how aircraft are built and maintained across its global fleet. Evolving from its first part, a spare crew seat component, Airbus has embraced additive manufacturing, taking it to new heights with more than 200,000 certified Stratasys polymer parts now in active service. Recent data shows that the implement...